Verve Therapeutics: VERVE-101 awarded Innovation Passport by UK MHRA

Verve Therapeutics announced that VERVE-101 has been awarded the Innovation Passport for the treatment of heterozygous familial hypercholesterolemia under the Innovative Licensing and Access Pathway by the Medicines and Healthcare products Regulatory Agency, the regulatory body of the United Kingdom. The ILAP aims to accelerate time to market and facilitate patient access to innovative medicines. VERVE-101 is a novel, investigational gene editing medicine designed to be a single-course treatment that permanently turns off the PCSK9 gene in the liver to durably lower disease-driving low-density lipoprotein cholesterol. Innovation Passport is the first step in the ILAP process and is awarded for a medicinal product addressing a condition that is life-threatening or seriously debilitating and where there is a significant patient or public health need.